Unbalanced expression of tissue inhibitors of metalloproteinases (TIMP) such as TIMP-1 relative to matrix metalloproteinases (MMPs) promotes progression of fibrosis in liver, lung, and kidney. As to therapeutic strategies, it would be advantageous to antagonize TIMP-1. MMP-9 binds TIMP-1 with high affinity (K i < 50 pM). Three histidine residues constitute the active site of the enzyme by binding the catalytic zinc. MMP-9 mutants were generated in which the histidine residues at position 401, 405 or 411, respectively, were replaced by alanine. All mutants were enzymatically inactive as demonstrated by gelatin zymography. In immuno-precipitation experiments, the MMP-9 mutant H401A bound 2-fold more efficiently to TIMP-1 than H405A, whereas H411A did not bind at all. The mutant H401A was approximately 3-fold less active in TIMP-1 binding than wild-type MMP-9. Recently, we established cell lines secreting TIMP-1 constitutively (HepG2-TIMP-1 cells). In this cell line, increased expression of TIMP-1 resulted in suppressed migration and enhanced cell-cell contact. In co-cultures of HepG2-TIMP-1 cells with HepG2 cells overexpressing the H401A mutant of MMP-9, the TIMP-1-associated phenotype was completely neutralized. These results suggest that a catalytically inactive metalloproteinase (e.g., MMP-9-H401A) that still binds TIMP-1 can be used as a specific antagonist of TIMP-1 activity in vivo.
the action of multiple MMPs, but are also known for a predominantly higher affinity toward certain MMPs (4, 5) . TIMP-1 and TIMP-3 preferentially bind to MMP-9, and TIMP-2 to MMP-2, respectively. TIMP-1 also binds, although less tightly, to MMP-3 and to progelatinase B (6) . The target of TIMP- 4 has not yet been published. TIMPs tightly bind to the active forms of MMPs forming 1:1 complexes, thus blocking their activity. TIMP-1, a 28.5 kDa glycoprotein with 12 cysteine residues, has been shown to form disulfide bonds in the inhibitor giving a 6-loop structure (7) . It is resistant to extremes of temperature and pH. In part this is thought to be due to the presence of six cysteine bridges presumed to maintain the structural integrity of the molecule (8) . TIMP-1 is synthesized by many different cells such as fibroblasts, monocytes, macrophages, chondrocytes, hepatocytes, and Ito cells (9, 10) . Synthesis of TIMP-1 is up-regulated by IL-6-type cytokines and transforming growth factor β. However, a specific down-regulation of TIMP-1 has never been observed. So far TIMP-1 mRNA expression was only decreased by dexamethasone and concanavalin A (9, 11) .
TIMP levels increase during acute and chronic liver injury and may add to the fibrotic buildup of ECM components by disturbing the balance between proteases and their inhibitors (12, 13, 14) . Therefore, a specific neutralization of TIMP-1 could be of therapeutical value. If liver injury has already led to extensive matrix accumulation, an accelerated matrix degradation would be useful. Fibrotic liver already has an increased fibrinolytic activity; unfortunately, it is inhibited by increased TIMP-1 activity (15) . Therefore, a specific inhibition of TIMP-1 activity would enhance matrix degradation, leading to amelioration.
Among all MMPs, MMP-9 binds to TIMP-1 with the highest affinity (3) . MMP-9 is a zincand calcium-dependent endopeptidase that is known to play a role in tumor cell invasion and destruction of cartilage in arthritis. The interaction of MMP-9 and TIMP-1 has been characterized as a slow but tight event, although the exact mechanism of complex formation is still unknown (16) . For MMP-1 it has recently been shown that the carboxyl-terminal domain is important for the initial, rapid binding of TIMP-1 and that this interaction contributes to the overall binding (17) .
The catalytic domain of all MMPs contains a conserved sequence HEXGHXXGXXHS that binds the catalytic zinc (18) . In MMP-9 this sequence starts with His401. Substitution of this histidine residue results in loss of enzymatic activity (19) . In the present study, we generated MMP-9 mutants in which all these histidine residues were individually replaced by alanine. We demonstrated a partial independence of catalytic activity and TIMP-1 binding capacity of MMP-9 and investigated functional activity of a novel TIMP-1-antagonist in a co-culture experiment with transfected hepatoma cells.
MATERIALS AND METHODS

Materials
The random primed DNA labeling kit, restriction enzymes, T4 DNA ligase, and Klenow enzyme were purchased from Boehringer Mannheim (Mannheim, Germany). MMP-9 standard, purified MMP-9 enzyme, and purified TIMP-1 were purchased from Chemicon International (Germany) and polyclonal antibodies against MMP-9 (C-terminal domain, M-17) from Santa Cruz (Santa Cruz, CA). [α-
32 P]dATP (110 TBq/mmol) was obtained from Amersham International (Amersham, UK). The entire coding region for rat MMP-9 crosshybridizing with human MMP-9 was a receipt from P. Mertens (Aachen). Preparation of a rabbit polyclonal anti-murine-TIMP-1 antiserum has been described (20) .
Construction of expression vectors
Standard cloning procedures were performed as described (21) . Construction of a eukaryotic TIMP-1 expression plasmid (pcDNA3.1 derivative) were described (20) .
To introduce a point mutation at amino acid 401 of murine MMP-9 (MMP-9-H401A), polymerase chain reaction (PCR) -aided mutagenesis was performed using the following primers: 5´-TGG CAG CGG CCG AGT TCG GCC ATG-3´ sense and 5´-CGA ACT CGG CCG CTG CCA CCA GG-3´ antisense.
To introduce a point mutation at amino acid 405 of murine MMP-9 (MMP-9-H405A), PCRaided mutagenesis was performed using the following primers: 5´-CAC GAG TTC GGC GCC GCAC-3´ sense and 5´-GTG CGG CGC CGA ACT CGT G-3´ antisense.
To introduce a point mutation at amino acid 411 of murine MMP-9 (MMP-9-H411A), PCRaided mutagenesis was performed using the following primers: 5´-GGG CTT AGA TGC CTC CAG CG-3´ sense and 5´-CGC TGG AGG CAT CTA AGC-3´ antisense.
Point mutations at amino acids 401 and 405 of MMP-9 (MMP-9-H401/405A) were introduced via PCR-aided mutagenesis using the following primers: 5´-GCC GCG GAG TTC GGC GCC GCA C-3´ sense and 5´-GTG CGG CGC CGA ACT CCG CGG C-3´ antisense.
All PCR-generated sequences were verified by automatically DNA sequencing (ABI Modell 373A). For preparation of DNA probes, the PRISM TM Ready Reaction DyeDeoxy TM Terminator Cycle Sequencing Kit (Perkin Elmer) was used.
Cells and cell treatment
Human hepatoma cells (HepG2) were cultured to 50-70% confluency in DMEM F-12 containing 10% fetal calf serum, streptomycin (100 mg/l), and penicillin (60 mg/l) at 5% CO 2 in a water-saturated atmosphere. Cells were transfected with expression vectors for murine TIMP-1, MMP-9, and MMP-9 mutants into HepG2 cells using a calcium phosphate precipitation technique as described (22) . Control cells received pRcCMV empty vector. HepG2 cells for transfection were subcultured for 16 h prior to the addition of the calcium phosphate precipitate; 18 h after transfection, the precipitate was removed and cells were cultured for 48 h in serum-free medium for zymography and Western blotting. Efficiency of transient transfection was 10-50% as determined by co-transfection with a β-galactosidase expression vector.
Selection of HepG2 clones stably transfected with murine TIMP-1 cDNA has been described (23) . For stable expression of MMP-9 mutants, HepG2 cells were transfected with the expression vector pcDNA3.1-MMP-9-mut containing the neomycin resistance gene. Colonies resistant to 500 µg/ml neomycin were isolated; four clones were established and assessed for the expression of mutant MMP-9 by Northern and Western blotting. Expression by these cells was maintained for more than 20 passages. To establish co-cultures equal amounts of HepG2 cells and stable transfected cells (either HepG2-TIMP-1 or HepG2-MMP-9-H401A) were mixed and cultured at least for two days to more than 80% confluency.
RNA isolation and Northern blot analysis
Total RNA was isolated from cells with the phenol extraction method as described (24) . Five micrograms of RNA were heated to 65 °C for 10 min in 50% formamide, 20 mmol/l 3-[Nmorpholino]propane sulfonic acid (MOPS), 5 mmol/l sodium acetate, 1 mmol/l EDTA, and 2.2 mol/l formaldehyde before gel electrophoresis in 1% agarose containing 2.2 mol/l formaldehyde, 20 mmol/l MOPS, 5 mmol/l sodium acetate, and 1 mmol/l EDTA. Equal loading of the RNA gel was checked by ethidium bromide staining of 18S and 28S ribosomal RNA. The separated RNA was transferred to Gene/Screen Plus membranes (DuPont-De-Nemours, Dreieich, Germany) according to the supplier's instructions. A 958-bp fragment coding for the N-terminal region of MMP-9 was excised from the pRcCMVGel-B vector (25) with the restriction endonucleases XhoI and XbaI. The filters were prehybridized at 68 °C for 2 h in 10% dextran sulfate, 1 M sodium chloride, and 1% SDS and hybridized in the same solution with cDNA fragments labeled by random priming (26) . After hybridization, unspecifically bound radioactivity was removed by washing in 2 x standard saline citrate solution (SSC) at room temperature, followed by two consecutive washes in 2 x SSC/1% SDS at 68 °C for 30 min each. The filters were then subjected to autoradiography with intensifying screens at -80 °C. Autoradiograms from at least three separate experiments were analyzed.
Western blot
SDS-polyacrylamide gel electrophoresis utilized separating gels of 7,5%, 10%, or 12,5% polyacrylamide and stacking gels of 3% polyacrylamide. Each lane was loaded with 2 µg of total protein. Upon electrophoresis at 30 mA, the proteins from serum-free cell supernatants were transferred onto a PVDF membrane (Pall Gelman Sciences, Rossdorf, Germany). Blotting procedure was controlled by staining with Ponceau S. Blots were blocked with TBS-N (pH 7.6), containing 10% BSA, 20 mM Tris.HCl, pH 7.5, 137 mM NaCl, 0.1% Nonidet P40, washed and incubated with polyclonal antibodies against MMP-9 (2 µg/ml TBS-N). Western blotting was followed by development with ECL (Amersham).
Zymography (assay for demonstration of MMP activity)
Serum-free medium of confluent HepG2 cells was concentrated 3-fold, assayed for protein content using the Bio-Rad protein assay kit and stored at -20 °C. MMP activity in the media was assessed by gelatin zymography following the method described previously (22) . The concentrated media were run on SDS/polyacrylamide gel (10%) containing 1 mg/ml gelatin. Each lane was loaded with equal amounts of total protein. After electrophoresis in 25 mM Tris base, 250 mM glycine, 1% SDS, the gel was washed at room temperature in 2.5% Triton X-100, 5 mM CaCl 2 , 50 mM Tris-HCl, pH 7.5, and incubated again in the same buffer for twice for 1 h. After rinsing the gel extensively with six changes of distilled water, it was incubated overnight (zymography) at 37 °C in 5 mM CaCl 2 , 50 mM Tris-HCl, pH 7.5 followed by Coomassie blue staining (0.5% wt/vol) and destaining in methanol / acetic acid / water (10:10:80). Gelatin zymography depicts MMPs as negatively stained bands of gelatinolytic activity.
Immunoprecipitation
To demonstrate TIMP-1 binding to MMP-9 mutants, COS-7 cells were metabolically labeled with [ 35 S]-methionine/cysteine for 6 h after transfection with expression vectors for MMP-9, MMP-9 mutants, and TIMP-1. After 1 h of chasing, supernatants were pretreated with pansorbin (Calbiochem, La Jolla, CA). In a 5-fold excess, MMP-9 and MMP-9 mutant supernatants were incubated with TIMP-1-bearing supernatants at 37 °C for 10 min. Subsequently mixtures were incubated with the appropriate antiserum for 3 h at 4 °C. The immunocomplexes were precipitated with protein A-Sepharose, separated on a 12.5% SDS polyacrylamide gel (27) , visualized by fluorography (28) , and analyzed densitometrically.
MMP gelatinase activity assay
Biotin-binding plates were covered with sample preparations and further processed according to the manufacturer's instructions (Chemicon international, Temecula, CA). Optical density as a read-out for gelatinase activity was measured at 450 nm on a microplate reader. Activity data were normalized by setting the activity of 20 ng MMP-9 to 1.0.
RESULTS
Cloning of MMP-9 mutants and expression in HepG2 cells
Three histidine residues constitute the active site of the MMP-9 enzyme by binding the catalytic zinc. Using PCR technology, all histidine residues in the catalytic domain of MMP-9 were subsequently replaced by alanine (Fig. 1 ).
HepG2 cells were transiently transfected with the expression vectors coding for MMP-9, MMP-9-H401A, MMP-9-H405A, MMP-9-H411A, and a double mutant (MMP-9-H401/405A). Serum-free supernatants were analyzed with a polyclonal antibody against MMP-9 by Western blotting. As shown in Fig. 2A , all MMP-9 mutants were expressed and secreted, albeit to different degrees. Since the smaller bands of approximately 72 kDa, 62 kDa, and 59 kDa were not observed in untransfected or mock-transfected HepG2 cells, they most likely represent N-terminal truncated (activated) forms of MMP-9.
To answer the question of whether all MMP-9 mutants exhibit gelatinolytic activity, we analyzed supernatants of transfected HepG2 cells by zymography. The results are shown in Fig. 2B . In contrast to wild-type MMP-9, the mutants (H401A, H405A, and H411A) were inactive toward gelatin substrate.
Identification of MMP-9 mutants retaining TIMP-1 binding ability
We tested whether catalytically inactive MMP-9 mutants were still able to bind TIMP-1. To measure complex formation of MMP-9 mutants with TIMP-1, we used metabolically labeled 35 S MMP-9 mutants, metabolically labeled 35 S TIMP-1 from transiently transfected COS-7 cells, and rat polyclonal antibodies against TIMP-1. The complexes were precipitated with protein A-Sepharose. No co-precipitation of mutant MMP-9-H411A was observed (Fig. 3A,  lane 6) . Densitometric analysis revealed a 3-fold lower binding capacity of MMP-9-H401A and a 6-fold lower of MMP-9-H405A compared to wild-type MMP-9 (Fig. 3B) . MMP-9 mutants were present in excess. To account for the lower expression level of some MMP-9 mutants, 5-fold more supernatant was used (compared to the TIMP-1-bearing supernatant) to exclude effects due to limiting amounts of MMP-9 mutants.
These data indicate that MMP-9-H401A, which has no gelatinolytic activity, is still able to bind TIMP-1. Whether the zinc binding region of MMP-9 is part of a binding site to TIMP-1 or is necessary for stabilizing other epitopes responsible for TIMP-1 interaction remains open.
Generation of HepG2 cell lines secreting constitutively large amounts of MMP-9 mutant H401A
HepG2 cells were transfected with the expression vector pcDNA3.1 containing the neomycin resistance gene and the entire coding region for the MMP-9 mutant H401A. Cells were selected in Neomycin-containing medium and multiple clones were analyzed by Northern blotting (Fig. 4A) . We isolated several clones expressing H401A. The clones #5, #24, and #48 were chosen for further experiments.
To demonstrate that MMP-9 is produced by positive clones, we carried out Western blots using polyclonal antibodies against MMP-9 (Fig. 4B) . H401A was running with a comparable electrophoretic mobility as recombinant human MMP-9 used as a positive control (Fig. 4B ). Small differences in mobility are attributed to the difference in molecular weight between human and mouse MMP-9. No measurable amounts of MMP-9 could be detected in wild-type HepG2 cells (Fig. 4B, lane 1) .
Abrogation of TIMP-1-associated growth behavior by MMP-9-H401A
Recently we showed that HepG2 cells stably transfected with cDNA coding for TIMP-1 do not grow as a monolayer. They grow in nests and lie on top of each other (23) . To test whether MMP-9-H401A is not only able to bind to TIMP-1 but also to neutralize TIMP-1 effects in vivo, we investigated the influence of mutant MMP-9 on the growth behavior of HepG2 cells secreting constitutively large amounts of TIMP-1 (Fig. 4C ). HepG2 cells stably transfected with mutant MMP-9 grow as monolayer (Fig. 4C, middle right) . Co-cultures of HepG2-TIMP-1 cells with HepG2-MMP-9-H401A cells completely abrogate the TIMP-1-associated phenotype (Fig. 4C, upper right) . For comparison, co-cultures of HepG2-TIMP-1 cells with wild-type HepG2 cells do not affect the typical TIMP-1-associated migration pattern (Fig. 4C, middle left) . Co-cultures of HepG2-MMP-9-H401A cells with wild-type HepG2 cells (Fig. 4C, lower panel right) and wild-type HepG2 cells (Fig. 4C , lower panel left) are shown as controls. Cell clones #24 and #48 secreting less amounts of MMP-9-H401A (Fig. 4B) showed also neutralizing, though less pronounced, effects on the TIMP-1 phenotype (data not shown).
Influence of MMP-9-H401A on relative MMP-9 activity in the presence of TIMP-1
To determine whether MMP-9-H401A is able to inhibit TIMP-1 in vitro, a modified MMP-9 activity assay was carried out using purified components and the serum-free supernatants of HepG2-MMP-9-H401A cells. To exclude potential side effects of HepG2 cell supernatant on MMP-9 activity, MMP-9 and MMP-9 plus TIMP-1 were added to serum-free wild-type HepG2 cell supernatant. Incubation of MMP-9 with TIMP-1 in equimolar amounts reduced total gelatinase activity by almost 50% (Fig. 5) . In the presence of 43 µl cell supernatant containing MMP-9-H401A, this loss of activity was almost completely abrogated, thereby demonstrating that the mutant MMP-9 is able to neutralize the ability of TIMP-1 to inhibit MMP-9 activity.
In addition, reverse zymography revealed that HepG2-MMP-9-H401A cells do not secrete any detectable amounts of TIMP-1 activity (data not shown). Wild-type HepG2 cells, however, showed low measurable levels of TIMP-1 (23) . Thus, one could envisage that MMP-9-H401A may be able to neutralize the endogenously expressed TIMP-1.
DISCUSSION
Over the last decade there have been major advances in understanding the cellular and molecular events involved in the pathogenesis of liver fibrosis. Increasing knowledge about cellular mechanisms of fibrosis would reveal new approaches to a more specific and effective therapy. Potential therapies in chronic liver diseases would aim at control of hepatic stellate cell activation, neutralization of proliferative and fibrogenic mediators, inhibition of matrix synthesis, and stimulation of matrix degradation. If chronic liver disease has already caused an excessive matrix accumulation, a stimulation of matrix degradation would be of significant importance. Until now, there was no way to apply proteases exogenously. Stimulation of endogenous proteases was successful in vitro only (29) .
Studies with cultured primary rat hepatocytes, hepatic stellate cells, rat models of liver fibrosis, and plasma levels in patients with chronic liver disease revealed that progressive fibrosis is associated with an increased TIMP-1 expression (9, 12, 13, 30).
There are many stimulators of TIMP-1 expression, but little is known about the downregulation of TIMP-1. Since the cloning of TIMP-1 in 1986, a reduction of TIMP-1 expression could be demonstrated only by dexamethasone and concanavalin A (9, 11). Histological findings from patients with liver fibrosis and from animal models of fibrosis indicate that recovery of liver fibrosis with diminution of excess extracellular matrix proteins is possible (31, 32 ). An increased collagenase activity during recovery could be detected as a key mechanism in spontaneous resolution of fibrosis in rat liver homogenates (15) . Since fibrotic liver already has an increased proteolytic activity (which is inhibited by high TIMP-1 activity, however) (15), our therapeutical approach aims at the inactivation of TIMP-1.
We chose MMP-9 for construction of TIMP-1 antagonists due to its high affinity (K i values < 50 pM) toward TIMP-1 (33) . The exact mechanisms of complex formation between TIMP-1 and MMP-9 are not yet clear. Concerning the binding of TIMP-1 to MMP-1, detailed studies favor a model of a non-competitive, two-step mechanism (33) . The first step is thought to be a fast, reversible complex formation, followed by a slow transformation into the final stable complex. The carboxy terminus of MMPs plays an important role in the initial fast binding step. The C-terminal domain of progelatinase B (Fig. 1) is not involved in autolytic or cellular activation and does not affect the catalytic activity of the enzyme. However, C-terminal domain interactions between active MMP-9 and TIMP-1 significantly enhance the rate of complex formation (33) . After shortening the carboxy terminus of MMP-9 by 125 amino acids, binding of TIMP-1 is reduced and completely abolished by truncating the C-terminus by 142 residues (E. Roeb et al., unpublished results). Moreover, this mutant does not show any MMP activity. Substrate binding is also reduced by that deletion, similar to that already described for MMP-2 (34) . From these experiments we conclude that an effective binding of TIMP-1 is only possible by retaining most of the hemopexin domain.
Antiproliferative and antifibrotic effects on cardiac fibrosis were associated with elevation of MMP-9 after treatment of cardiac fibroblasts with mimosine, a prolyl 4-hydroxylase inhibitor (35) . In liver cirrhosis in rats, an OK-432 (a biological response modifier) induced increased production of MMP-9 improved fibrotic processes (36) . Our aim was to mutate MMP-9 in order to delete the aggressive proteolytic activity without disturbing the possibility of tight binding to TIMP-1. All MMP-9 mutants were expressed and secreted after transient transfection of HepG2 cells, as shown in Fig. 2A . Differences between detection of MMP-9 mutants might be an effect of different expression. None of the MMP-9 mutants had any proteolytic activity. Thus, the replacement of one amino-acid (histidine) by alanine is sufficient to inactivate MMP-9.
We demonstrated that inactivated MMP-9 is still able to bind to TIMP-1 (Fig. 3) , thus proving a partial independence of catalytic activity and TIMP-1 binding capacity of MMP-9. However, TIMP-1 binding capacity of wild-type MMP-9 is about 3-fold higher than that of MMP-9-H401A. The structure of MMP-2 that shows the highest homology to MMP-9 within the family of the MMPs was recently solved by X-ray crystallography (37) .
Comparison of this structure with the structure of MMP-3 in complex with TIMP-1 revealed that the MMP-2 propeptide binds in a very similar manner to the active site of MMP-2 as TIMP-1 to MMP-3 (38) . In the latter complex, the histidine that corresponds to H411 in MMP-9 is part of the MMP-3/TIMP-1 interface and therefore crucial not only for Zn binding, but also for the MMP/TIMP interaction. Since MMP-9-H411A is not able to bind TIMP-1 at all, we propose a similar function for H411 in MMP-9. This structural comparison also rationalizes the graduate effects in TIMP-1 binding seen with the other two MMP-9 mutants. Whereas the histidine corresponding to H401 in MMP-9 is mostly buried in the catalytic domain and has no direct contact to TIMP-1, the histidine corresponding to H405 is at least partially accessible and is located at the edge of the MMP-3/TIMP interface.
To study the effects of the mutant MMP-9-H401A in vivo, we transfected HepG2 cells with an expression plasmid coding for this protein. To minimize differences in transfection efficiency, we established cell lines stably transfected with that MMP-9 mutant. Three cell lines were characterized and behaved similarly concerning the secretion of MMP-9-H401A (Fig. 4B ) and the growth pattern (Fig. 4C) . These cells show a similar growth pattern compared with wild-type cells, but their cell-cell contact seems to be reduced. They grow in a monolayer and wide spread, in contrast to almost cubic HepG2 wild-type cells.
In previous reports, we have demonstrated an altered phenotype of stably transfected cells engineered to express mouse TIMP-1 (23), a phenomenon that has been shown to be independent of the cell type (23) . In co-cultures of stably transfected HepG2-TIMP-1 cells with stably transfected HepG2-MMP-9-H401A cells, the TIMP-1-associated growth behavior is completely abrogated. Neutralization of the TIMP-1-associated phenotype was seen by the HepG2-MMP-9-H401A cells but not by wild-type HepG2 cells. This is the first in vivo effect of the MMP-9 mutant H401A and demonstrates that this mutant is not only able to bind TIMP-1, but also to neutralize TIMP-1 in cell culture. By a modified gelatinase activity assay, we could demonstrate that the mutant MMP-9-H401A is also able to neutralize the ability of TIMP-1 to inhibit MMP activity in an in vitro system. Further experiments are necessary to test whether this mutant is able to inhibit other TIMP-1-associated phenotypes, i.e., fibrotic processes.
In conclusion, we demonstrated a partial independence of catalytic activity and TIMP-1 binding capacity of MMP-9 and showed that the TIMP-1-associated phenotype of liver cells was completely neutralized by an inactivated MMP-9. We anticipate that our findings will influence the design of future antifibrotic strategies in progressive liver fibrosis.
Figure 1. Domain structure of MMP-9
Similar to other enzymes of the MMP family, MMP-9 has a propeptide, a catalytic domain, and a C-terminal hemopexin domain (39) . Three MMP-9 mutants in which the histidine residues at position 401, 405, or 411, respectively, were replaced by alanine (A) are indicated. These three histidine residues constitute the binding site for the catalytic zinc. 
